Novo Nordisk Foundation Commits $135M to New Cell Therapy Facility
Location aims to translate research into multiple real-world treatments.
With the goal of translating breakthroughs in cell therapy research into real-world treatments for people with diseases such as chronic heart failure, Parkinson’s, kidney disease, type 1 diabetes, and several forms of cancer, the Novo Nordisk Foundation has officially dedicated approximately $135 million to a new cell therapy facility. Located at the Technical University of Denmark (DTU) in Lyngby, the center will serve public, private, national, and international clients from academia, biotech, and the pharmaceutical industry. It is expected to be ready in 2027.
“Cell therapies have the potential to take us from treating or managing the symptoms of chronic diseases to treating the disease itself, or even curing it with a one-off procedure,” says Thomas H.R. Carlsen, CEO, the Novo Nordisk Foundation Cellerator. “We’ve seen major advances in the laboratory in recent years, but many promising cell therapy candidates face difficulties reaching clinical trials, partly because we can’t currently develop cell therapy products in large, consistent quantities here in Denmark. I’m thrilled to be heading an initiative that will change this and provide hope to people living with chronic diseases.”
Reference: New cell therapy facility enters fight against chronic diseases. Novo Nordisk Fonden. September 21, 2023. Accessed September 22, 2023. https://novonordiskfonden.dk/en/news/new-cell-therapy-facility-enters-fight-against-chronic-diseases/
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
